COVID-19 is caused by SARS-CoV-2 has impacted our lives, jobs, families, and relationships for over a year now. Vaccinations have hit the market, and healthcare workers have been working tirelessly on vaccinating, and treating patients with COVID-19. Medications have had some effect on the virus but there is no cure.
A longstanding zero-tolerance cannabis policy could be slowly eroding in the military. Earlier in July, a House committee approved a provision that would let troops who previously used cannabis to re-enlist.
Researchers suggested that baldness should be considered a risk factor, dubbing it the ‘Gabrin sign’. Bald men may be at higher risk of suffering from severe Covid-19 symptoms, emerging evidence suggests.
A study of 4532 men in the Veneto region of Italy has found that those who were being treated for prostate cancer with androgen-deprivation therapies (ADT) were less likely to develop the coronavirus COVID-19 and, if they were infected, the disease was less severe.
Applied Botanics Acquires Intellectual Property Rights to a Novel Cannabinoid Based Therapy Under Development for COVID-19
Applied Botanics, LLC. (“Applied Botanics”) announced today it has acquired from Applied Biology, Inc. intellectual property rights to a novel cannabinoid based therapy under development for COVID-19 and other respiratory illnesses. “We are passionate about the evolving field of cannabinoids (CBD) research and are excited to be working with Dr. Goren and this distinguished team of scientists on such a monumental and potentially impactful project,” states Kawel LauBach, Applied Botanics Chief Executive Officer.
Applied Biology in Collaboration with Brown Researchers Announce the Discovery of a Possible Association Between the Genetic Cause of Hair Loss and Severity of COVID-19 Infection
In a joint research effort studying the genetics of the androgen receptor in androgenetic alopecia, scientists discover a possible genetic variation that pre-disposes COVID-19 patients to develop severe symptoms.